P3 Health Partners Inc. Announces Appointment of Chief Clinical Officer
P3 Health Partners appointed Dr. Michael Millie as Chief Clinical Officer, effective October 12, 2026. In connection with the hire, the board's Compensation and Nominating Committee granted Dr. Millie an inducement stock option to purchase 110,000 Class A shares under Nasdaq Rule 5635(c)(4), with a ten-year term and 25% annual vesting over four years.
Key figures
- Vesting
- 25% annually over four years
- Option term years
- 10
- Inducement option shares
- 110000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.